Accurate staging and molecular characterization are foundational for managing gastric adenocarcinoma. Because early-stage gastric tumors often present with vague symptoms, clinical staging combines endoscopic imaging, tissue biopsies, and advanced cross-sectional scans to map regional depth and distant spread. Modern protocols emphasize mandatory biomarker testing at the initial diagnostic phase to determine targeted systemic therapy eligibility.
[Diagnostic Endoscopy & Biopsy]
│
▼
[Molecular Biomarker Profiling] ──► (HER2, PD-L1, MSI/dMMR, CLDN18.2)
│
▼
[Clinical Staging (CT/EUS/Laparoscopy)]
│
├─► Early (T1a) ──────────────► Endoscopic Resection (EMR/ESD)
├─► Localized (T1b-T4) ───────► Perioperative Chemo/IO + Surgical Resection
└─► Metastatic (M1) ──────────► Biomarker-Targeted Systemic Therapy
Core Diagnostic and Staging Modalities
Determining disease extent requires a combination of structural imaging, tissue sampling, and functional evaluation to avoid under-staging.
- Upper Gastrointestinal Endoscopy: The gold standard for initial visualization and tissue biopsy. High-definition chromoendoscopy assists in identifying subtle mucosal lesions.
- Endoscopic Ultrasound (EUS): Evaluates depth of tumor wall invasion (T-stage) and detects localized perigastric lymph node involvement (N-stage).
- Contrast-Enhanced CT and PET Scans: Contrast CT of the chest, abdomen, and pelvis assesses distant organ involvement (M-stage). Integrated FDG-PET/CT helps identify occult distant metastases.
- Diagnostic Laparoscopy with Cytology: Recommended for locally advanced disease (cT3/cT4) to rule out radiologically invisible peritoneal seeding before intent-to-cure treatment.
Molecular Biomarker Profiling Benchmarks
Biomarker panels inform systemic treatment choices for advanced, recurrent, or metastatic gastric cancers.
BiomarkerDiagnostic Test MethodClinical RelevanceHER2 (ERBB2)IHC / FISHDictates eligibility for HER2-targeted agents (e.g., trastuzumab, trastuzumab deruxtecan).PD-L1IHC (CPS / TAP score)Predicts responsiveness to immune checkpoint inhibitors (e.g., pembrolizumab, nivolumab).MSI / dMMRIHC / PCR / NGSIdentifies high microsatellite instability; guides perioperative or metastatic immunotherapy.Claudin 18.2 (CLDN18.2)IHCDetermines candidacy for targeted monoclonal antibodies (e.g., zolbetuximab).
Curative and Palliative Treatment Pathways
Multidisciplinary tumor boards tailor treatment plans based on pathological staging and patient functional status.
Endoscopic and Surgical Interventions
Superficial mucosal tumors (T1a) without ulcerative features may be treated via Endoscopic Mucosal Resection (EMR) or Endoscopic Submucosal Dissection (ESD). For invasive localized disease (T1b through T4), surgical options include subtotal, total, or proximal gastrectomy combined with D2 lymph node dissection to ensure clear surgical margins.
Perioperative Systemic Therapies
Resectable locally advanced tumors benefit from perioperative chemotherapy regimens (such as FLOT: fluorouracil, leucovorin, oxaliplatin, and docetaxel). Incorporating immune checkpoint inhibitors into perioperative protocols enhances pathologically complete response rates in biomarker-selected populations.
Advanced and Metastatic Disease Management
When distant metastases are present, systemic therapy serves as the primary treatment. Chemotherapy backbones are combined with targeted antibodies or immunotherapies according to the patient's biomarker profile (such as HER2 positivity, PD-L1 expression, or CLDN18.2 expression).
Conclusion
Gastric cancer diagnosis and treatment rely on a combination of precision imaging, surgical techniques, and biomarker-driven systemic care. Early staging through endoscopy, EUS, CT imaging, and staging laparoscopy establishes disease distribution. Concurrently, routine profiling for HER2, PD-L1, MSI, and CLDN18.2 guides personalized targeted therapies and immunotherapies. Following an evidence-based, multidisciplinary approach optimizes surgical outcomes, extends overall survival, and preserves functional quality of life for patients across all disease stages.